Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Noel

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Annals of Hematology|April 7, 2018
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patientsVerónica González-Calle, Abigail Slack, Niamh Keane, et al.
Blood|December 10, 2016
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyDelphine Rea, Franck E Nicolini, Michel Tulliez, et al.
NPJ Genomic Medicine|September 2, 2025
Author Correction: A founder BRCA1 exonic duplication involving breakpoint in T2T reference genome-specific region results in constitutional fusion transcriptMathias Schwartz, Mathilde Filser, Kevin Merchadou, et al.
NPJ Genomic Medicine|July 31, 2025
A founder BRCA1 exonic duplication involving breakpoint in T2T reference genome-specific region results in constitutional fusion transcriptMathias Schwartz, Mathilde Filser, Kevin Merchadou, et al.
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Annals of Hematology|April 7, 2018
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patientsVerónica González-Calle, Abigail Slack, Niamh Keane, et al.
Blood|December 10, 2016
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyDelphine Rea, Franck E Nicolini, Michel Tulliez, et al.
NPJ Genomic Medicine|September 2, 2025
Author Correction: A founder BRCA1 exonic duplication involving breakpoint in T2T reference genome-specific region results in constitutional fusion transcriptMathias Schwartz, Mathilde Filser, Kevin Merchadou, et al.
NPJ Genomic Medicine|July 31, 2025
A founder BRCA1 exonic duplication involving breakpoint in T2T reference genome-specific region results in constitutional fusion transcriptMathias Schwartz, Mathilde Filser, Kevin Merchadou, et al.
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Pageof 7